Trial Profile
A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 12 May 2012 New trial record